May 2024 Content Release Copied
Clinical Profile Documentation
Additions
The Problems > Add Details area is updated with applicable documentation points for the following diagnoses.
- HER-2/neu status is no longer available for Bile Duct Cancer (Parent) and Gallbladder
- HER-2/neu Value-ISH is no longer available for Bile Duct Cancer (Parent) and Gallbladder Cancer.
- HER2/neu results (via NGS, ISH, ) is now available for Bile Duct Cancer (Parent) and Gallbladder Cancer with the following documentation points:
- Positive
- Negative
- Unknown
Lab Analytes & Panels
Additions
- A – Beta-amyloid 42/40
- Adenosine deaminase pleural fluid, U/L
- Albumin, random urine w/o creatinine panel
- Aldosterone urine, ug/L
- Apolipoprotein E genotype, comments
- Apolipoprotein E genotype, methods
- Apolipoprotein E genotype, references
- ATN Profile panel
- ATN SUMMARY [1]
- quintana IgG titer panel
- Bartonella quintana AB, IgG, screen panel
- Bartonella quintana AB, IgM, screen panel
- Beta-amyloid 40
- Beta-amyloid 42
- Celiac disease antibody evaluation panel
- CSF fungus culture
- CSF fungus culture panel
- Cytomegalovirus (CMV) IgM panel
- ENA screen interpretation
- Endomysial antibody, IgA panel
- Ferritin, serum, ug/L
- Fungus culture, blood
- Fungus culture, blood panel
- Hemoglobin variant by mass spectrometry panel
- Hepatitis delta virus, qual
- Hepatitis delta virus panel
- Hepatocellular carcinoma panel
- Histoplasma antibody by immunodiffusion panel
- HSV 2 IgG result
- Immune complex, EU/mL
- Information:
- Intrinsic factor blocking antibody panel
- JO-1 antibody, CU
- Medical device aerobic culture
- Medical device aerobic culture panel
- Metanephrines fract, free, blood panel
- Myeloma, FISH, fixed cells
- Myeloma, FISH, fixed cells panel
- N — NfL, plasma
- Ova + parasite exam, urine
- Sjogren’s panel with rheumatoid factor and ANA, IFA with reflex
- Sjogren’s panel with rheumatoid factor and ANA, IFA with reflex panel
- SSB antibody, CU
- T — p-tau181
- T-transglutaminase (tTG), serum IgG, CU
- Thalassemia summary interpretation
- Thalassemia summary review by
- Treponema pallidum ab panel
- WBC/NUC cells, fluid, %
- Wright stain smear
Medications
Updates
| Medication | Update |
| IGM-8444 invest IV | New Alias available: Aplitabart invest |
| ALLO-501A invest IV | New Form available: 20x10e6 cells/mL solution |
| BA3071 invest IV | Updated Form: 40 mg/mL solution |
| ART6043 invest Oral | New Form available: 200 mg tablet |
| ACE2016 invest IV | New drug |
| ABT 234 or Pembrolizumab invest IV | New drug |
| Naporafenib invest Oral | New Forms available: 50 mg tablet and 75 mg tablet |
| KSQ-4279 invest Oral | Renamed to RO76230066 invest Oral |
| Ofatumumab IV | Updated instructions |
Regimen Library
Additions
Pemrydi RTU
To improve ease of ordering, a new unchecked Pemrydi RTU (Pemetrexed IV) order has been added to all regimen templates containing Pemetrexed IV.
The following regimens have been added into the library.
| Regimen Name | Diagnosis |
| Epirubicin D1,2 + Ifosfamide D1-5 Q21D | Sarcoma, Soft Tissue (Parent) |
| Gemcitabine D1,8,15 + Trastuzumab IV D1,8,15,22 Q28D | Breast Cancer |
| Pembrolizumab (Dose Banding) + Paclitaxel D1,8,15,22,29,36 + Carboplatin D1,8,15,22,29,36
Q42D fb Pembrolizumab (Dose Banding) + Doxorubicin + Cyclophosphamide (AC) Q42D |
Breast Cancer |
| Pemivibart (Pemgarda) (COVID-19 Pre-Exposure Prophylaxis) | All Problems |
| Talquetamab-tgvs SQ Option D1,3,5,7 (Biweekly Dosing: Initial) | Multiple Myeloma (MM) |
| Teclistamab-cqyv SQ Option D1,3,5 (Initial) | Multiple Myeloma (MM) |
| VTD-PACE | Multiple Myeloma (MM) |
Updates
Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.
- Bile Duct Cancer (Parent)
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Fallopian Tube Cancer
- Gallbladder Cancer
- Head and Neck Cancer (Parent)
- Leukemia, Chronic Lymphocytic (CLL)
- Lung Cancer, Non-small Cell (NSCLC)
- Lymphoma, Hodgkin (HL)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Melanoma, Skin
- Ovarian and Primary Peritoneal Cancer
- Renal Cell Carcinoma (RCC)
- Renal Pelvis and Ureter Cancer
- Urethral Cancer
- Uterine Cancer (Parent)
- Waldenstrom’s Macroglobulinemia
Research
Starting Monday, June 10, 2024, Sarah Cannon Research Institute will manage all SCRI/USOR trials and trial regimens. For questions about these trials and regimens, please contact SCRI.DLEMRAnalysts@scri.com.
Updates
| Updated Reference Information | Updated Drug Service Order Information | Other Changes | |
| USOR 21527 | X | ||
| USOR 22124 | X | ||
| USOR 22181 | X | X | No longer available:
Now available:
|
| USOR 22258 | X | ||
| USOR 23055 | X | ||
| USOR 23078 | X | ||
| USOR 23094 | X | ||
| USOR 23095 | X | ||
| USOR 23116 | X | ||
| USOR 23129 | X | Now available:
USOR 23129 Arm A ONC-392 + Lutetium Lu 177 vipivotide tetraxetan Q42D |
|
| USOR 23228 | X | ||
| USOR 23229 | X | X |
Billing & HCPCS Codes
Updates
| Medication | HCPCS Codes |
| Docetaxel | J9999 per 80 mg |
| Secukinumab IV | J3590 per 125 mg |
| Tocilizumab-aazg IV (Tyenne) | J3590 per
|
| Tc-99m-sod pyroph IV (Technescan Pyp IV) | Q9969 per 1 dose |
| Nogapendekin alfa inbakicept-pmln Intravesical | J9999 per 400 mcg |
NDC to HCPCS Crosswalk
Additions
| Medication (Brand) | HCPCS Code | NDC |
| Risperidone (Rykindo) | J2801 per 0.5 mg |
|